ArticleDrug design, development and therapy2026
Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The quantitative exposure-response-toxicity relationships for flumatinib have yet to be established in chronic-phase chronic myeloid leukemia (CML-CP) patients. Methods: We investigated associations between steady-state flumatinib plasma concentrations and clinical efficacy/adverse events in CML-CP patients. Results: Flumatinib exposure exhibited dose-dependent pharmacokinetics. In first-line patients, responders achieving major molecular response (MMR) exhibited significantly higher C Conclusion: Flumatinib demonstrates exposure-efficacy-toxicity relationships in Chinese patients with CML-CP. These exploratory findings suggest potential concentration thresholds that may inform future therapeutic drug monitoring strategies, pending prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.